Gal-3 does not suppress cisplatin-induced apoptosis in A-375 melanoma cells

Cell Biol Int. 2016 Apr;40(4):428-38. doi: 10.1002/cbin.10582. Epub 2016 Feb 18.

Abstract

Melanoma is the most aggressive of all skin cancers and is exceptionally resistant to therapies. During melanoma progression, cancer cells reprogram their proliferation and survival pathways and achieve resistance to treatment-induced apoptosis. Galectin-3 (gal-3) is a member of the lectin family and is involved in such biological processes as cell adhesion, growth and differentiation, the cell cycle, and apoptosis. Gal-3 also plays an important role in tumor development and metastasis. The relationship between gal-3 expression and these processes is specific to the tumor type and the stage of cancer progression. The biological functions of gal-3 depend on its localization in the cell. In the present study, human metastatic melanoma A-375 cells, characterized by weak endogenous expression of gal-3, were transfected with gal-3 cDNA and cisplatin-induced apoptosis was measured. Data from AnnexinV and mitochondrial membrane potential analysis revealed that gal-3 did not protect the A-375 melanoma cells against cisplatin. This result probably is associated with its nuclear localization in the cells.

Keywords: A-375 cell line; apoptosis; cancer; galectin-3; melanoma; transfection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Apoptosis / drug effects*
  • Caspase 3 / metabolism
  • Cell Line, Tumor
  • Cisplatin / pharmacology*
  • Galectin 3 / genetics
  • Galectin 3 / metabolism*
  • Humans
  • Melanoma / metabolism
  • Melanoma / pathology
  • Membrane Potential, Mitochondrial / drug effects
  • Microscopy, Fluorescence
  • Real-Time Polymerase Chain Reaction
  • Transfection

Substances

  • Antineoplastic Agents
  • Galectin 3
  • Caspase 3
  • Cisplatin